147 0.020(0.014) 0.779 1.004 0.976-1.032 ≤ 65 53 >65 36 NSCLC histology (AJCC grade) I 33 0.016 0.354(0.146) 0.049 1.368 1.001-1.868 II III 56 IV SOX9 0.000 0.776(0.199) 0.001 2.004 1.350-2.974 Low 44 High 45 The expression level of SOX9 protein in NSCLC was significantly correlated with patients’ survival time (P < 0.05); the correlation coefficient was -0.262, indicating that higher levels of SOX9 expression was correlated with shorter survival time. The prognostic value of SOX9 expression in different subgroups of NSCLC patients was stratified in relation to the histological
staging. Trametinib A significant correlation was found between high SOX9 expression and shorter overall survival time in AJCC-graded subgroups of NSCLC. Patients with tumors exhibiting high SOX9 expression had significantly shorter overall survival than those with low expression of SOX9 in either stages I + II subgroup (n = 43; P = 0.001, log-rank; Figure 5A) or stages III + IV subgroup (n = 56; P = 0.020, log-rank; Figure 5B), indicating that SOX9 could be a valuable prognostic marker for NSCLC patients at all disease stages. Figure 5 Kaplan-Meier analysis showing the overall survival of NSCLC patients categorized according to the AJCC grades and status of SOX9 expression. The statistical significance of the difference
KU57788 between curves of SOX9 high-expressing and low-expressing Cediranib (AZD2171) patients was compared within subgroups of AJCC grades I+II (A) and III+IV (B). P values were calculated by the log-rank test. Discussion The major finding of our study is that the progression of
human NSCLC is related to upregulation of SOX9 expression. Although, a previous report has described a correlation between the expression of SOX9 mRNA and protein levels with lung adenocarcinoma [6], this study represents the first demonstration that SOX9 mRNA and protein are upregulated in all stages of human NSCLC and that this degree of upregulation increases as NSCLC progresses to advanced stages. Recent cogent evidence has provided a link between SOX9 and cancer development and progression [14, 15], and the upregulation of SOX9 has been observed in several types of solid tumors, including lung adenocarcinoma, breast carcinoma, colorectal cancer, and prostate cancer [6–9]. In addition, there is marked inhibition of differentiation, coupled with an expanded domain of expression of SOX9 protein in Nmyc overexpressing lung [16]. It has been reported that the induction of SOX9 expression could be induced through various mechanisms. Dysregulation of tissue development pathways can be conducive to cancer initiation and progression. As part of a developmental pathway, elevation of SOX9 in prostate neoplasia promotes tumor cell proliferation [17].